6 Integrated Clinical Cases and Review
Connects immune deficiencies, autoimmune disease, and immunosuppressive treatment to infection risks and safe clinical next steps.
Three routes to immune problems
Immune problems can arise from inadequate immune defense, immune activity directed against the body's own tissues, or deliberate suppression of immune activity. These problems can overlap: autoimmune disease may damage tissues, while treatment for that disease can weaken defenses against infection.
In transplant care, helps prevent rejection but increases susceptibility to infection. Clinical decisions therefore involve weighing these risks, and new symptoms or treatment questions call for timely assessment by the relevant clinical team.
Recognizing impaired antibody defense
Antibodies help defend against many bacterial infections and some intestinal pathogens. Persistently low immunoglobulin levels alongside repeated bacterial sinus and lung infections and several Giardia infections are consistent with impaired .
Such a pattern warrants evaluation for an immune deficiency rather than assuming the infections are unrelated. The clinical pattern suggests a possible immune problem; it does not by itself establish a diagnosis.
Autoimmune disease and infection risk
Lupus is an autoimmune disease in which immune activity can injure the body's own tissues, including the kidneys. A patient with lupus nephritis who takes prednisone and mycophenolate may develop a fever and new cough, but these symptoms should not automatically be assumed to represent a lupus flare.
Infection must remain high on the differential because prednisone and mycophenolate suppress immune defenses and can increase infection risk. The treatment trade-off is controlling autoimmune disease while also managing risks such as infection. Prompt clinical assessment is safer than automatically increasing .
Reviewing tuberculosis risk before therapy
Before a patient with rheumatoid arthritis starts a , the care team should clarify any past positive TB test and whether treatment was received, then evaluate for TB infection or disease with the prescribing team. These medications suppress immune activity and can raise the risk that TB infection progresses to active disease.
A positive TB test alone does not distinguish latent infection from active TB. Clinical evaluation is needed, and active disease must be excluded before latent-TB treatment is started.
Responding to possible
Missing doses of tacrolimus can leave a transplanted kidney vulnerable to . Reduced urine output after missed doses is a serious concern, even without fever, but it can also have other causes. The transplant team should be contacted promptly to assess graft function and determine the cause.
Do not independently stop, restart, or adjust tacrolimus. Medication changes can affect both rejection risk and infection risk, so the transplant team must guide them.
Assessing possible infection after transplant
After a solid-organ transplant, fever and unusual fatigue warrant prompt contact with the transplant team for individualized assessment; symptom mildness alone is not a safe reason to wait. increases infection risk, and symptoms may not reliably reflect how severe an infection is.
Risk varies with factors such as time since transplant, treatment intensity, and clinical circumstances. There is no single risk profile that applies to every recipient.
Reviewing vaccines during
Before vaccination, check whether a is safe for the person's degree of and treatment. Live vaccines are generally avoided in severe because the weakened organism may still cause harm.
For a , the principal concern is often that the immune response may be reduced, rather than that the vaccine will cause infection. Vaccine choice and timing should be reviewed with the treating clinician.